CARDINAL HEALTH INC
CAHAPI behind this page
CAH Q3 2026 request
Playground key active
/api/financials?ticker=CAH&year=2026&quarter=3
Pick an endpoint and run the request.Income Statement
| Metric | Q3 2026 | Q3 2025 | YoY |
|---|---|---|---|
| Revenue | 60,940 | 54,878 | +11.0% |
Show Business Segments breakouts |
|||
| All Other Segments · at-Home Solutions [Member] | 1,128 | 817 | +38.1% |
| All Other Segments · Nuclear Precision Health Services [Member] | 478 | 403 | +18.6% |
| All Other Segments · Operating Segments | 1,706 | 1,304 | +30.8% |
| All Other Segments · OptiFreight Logistics [Member] | 100 | 84 | +19.0% |
| Cost of product sold · Operating Segments | 3,148 | 3,160 | -0.4% |
| Pharmaceutical and Specialty Solutions · Operating Segments | 56,111 | 50,433 | +11.3% |
Show Geography breakouts |
|||
| Non Us | 423 | 399 | +6.0% |
| US | 60,542 | 54,498 | +11.1% |
Show Consolidation Items breakouts |
|||
| Corporate Non Segment | -25 | -19 | -31.6% |
| Operating Segments | 60,965 | 54,897 | +11.1% |
| Cost of Revenue | 58,442 | 52,755 | +10.8% |
Show Business Segments breakouts |
|||
| All Other Segments · Operating Segments | 1,268 | 975 | +30.1% |
| Cost of product sold · Operating Segments | 2,605 | 2,634 | -1.1% |
| Pharmaceutical and Specialty Solutions · Operating Segments | 54,595 | 49,167 | +11.0% |
Show Consolidation Items breakouts |
|||
| Operating Segments | 58,468 | 52,776 | +10.8% |
| Gross Profit | 2,498 | 2,123 | +17.7% |
| Selling, General & Administrative | 1,542 | 1,315 | +17.3% |
Show Business Segments breakouts |
|||
| All Other Segments · Operating Segments | 259 | 195 | +32.8% |
| Cost of product sold · Operating Segments | 518 | 487 | +6.4% |
| Pharmaceutical and Specialty Solutions · Operating Segments | 732 | 604 | +21.2% |
Show Consolidation Items breakouts |
|||
| Operating Segments | 1,509 | 1,286 | +17.3% |
| Restructuring Charges | 25 | 28 | -10.7% |
| Amortizationandotheracquisitionrelatedcosts | 114 | 152 | -25.0% |
| Acquisition Related Cash And Share Based Compensation Costs | 112 | 20 | +460.0% |
| Gain Loss On Sales Of Assets And Asset Impairment Charges | 185 | -17 | +1188.2% |
| Gain Loss Related To Litigation Settlement | 11 | -105 | +110.5% |
| Operating Income | 509 | 730 | -30.3% |
Show Business Segments breakouts |
|||
| All Other Segments · Operating Segments | 179 | 134 | +33.6% |
| Cost of product sold · Operating Segments | 25 | 39 | -35.9% |
| Pharmaceutical and Specialty Solutions · Operating Segments | 784 | 662 | +18.4% |
Show Consolidation Items breakouts |
|||
| Corporate Non Segment | -479 | -105 | -356.2% |
| Operating Segments | 988 | 835 | +18.3% |
| Other Non-Operating Income (Expense) | 16 | -9 | +277.8% |
| Interest Expense | 101 | 74 | +36.5% |
| Income Before Taxes | 392 | 665 | -41.1% |
| Income Tax Expense (Benefit) | 12 | 157 | -92.4% |
Show Goodwill Impairment [Axis] breakouts |
|||
| Pharmaceutical and Specialty Solutions | 23 | — | — |
| Net Income | 380 | 508 | -25.2% |
Show Equity Components breakouts |
|||
| Noncontrolling Interest | -19 | 2 | -1050.0% |
| Net Income Loss Attributable To Noncontrolling Interest | 19 | -2 | +1050.0% |
| Net Income | 399 | 506 | -21.1% |
| Income Loss From Continuing Operations Per Basic Share | 1.69 | 2.11 | -19.9% |
| Income Loss From Continuing Operations Per Diluted Share | 1.69 | 2.1 | -19.5% |
| Wtd Avg Shares (Basic) | 235 | 240 | -2.1% |
| Wtd Avg Shares (Diluted) | 236 | 241 | -2.1% |
| Common Stock Dividends Per Share Declared | 0.51 | 0.51 | +1.0% |
| Total Costs & Expenses (Q) | — | — | — |
Show Business Segments breakouts |
|||
| All Other Segments · Operating Segments | 1,527 | 1,170 | +30.5% |
| Cost of product sold · Operating Segments | 3,123 | 3,121 | +0.1% |
| Pharmaceutical and Specialty Solutions · Operating Segments | 55,327 | 49,771 | +11.2% |
Show Consolidation Items breakouts |
|||
| Operating Segments | 59,977 | 54,062 | +10.9% |
| Comprehensive Income | 391 | 510 | -23.3% |
| Other Comprehensive Income | -8 | 4 | -300.0% |
Balance Sheet
| Metric | Q3 2026 | Q3 2025 | YoY |
|---|---|---|---|
| Current Assets | |||
| Cash & Cash Equivalents | 3,937 | 3,326 | +18.4% |
| Receivables Net Current | 13,648 | 12,666 | +7.8% |
| Inventory | 18,007 | 16,158 | +11.4% |
| Other Assets Current | 2,472 | 2,398 | +3.1% |
| Total Current Assets | 38,064 | 34,595 | +10.0% |
| Non-Current Assets | |||
| Property, Plant & Equipment | 2,928 | — | — |
Show Geography breakouts |
|||
| Non Us | 434 | — | — |
| US | 2,494 | — | — |
| Other Non-Current Assets | 1,999 | 1,598 | +25.1% |
| Total Assets | 56,689 | 49,871 | +13.7% |
Show Business Segments breakouts |
|||
| All Other Segments · Operating Segments | 4,065 | 2,726 | +49.1% |
| Cost of product sold · Operating Segments | 6,888 | 7,201 | -4.3% |
| Pharmaceutical and Specialty Solutions · Operating Segments | 41,032 | 35,734 | +14.8% |
Show Consolidated Entities breakouts |
|||
| Variable Interest Entity Primary Beneficiary | 1.2 | 524 | -99.8% |
Show Consolidation Items breakouts |
|||
| Corporate Non Segment | 4,704 | 4,210 | +11.7% |
| Goodwill | 11,415 | — | — |
Show Business Segments breakouts |
|||
| All Other Segments | 1,747 | — | — |
| Pharmaceutical and Specialty Solutions | 9,668 | — | — |
| Intangible Assets | 2,258 | 2,095 | +7.8% |
Show Finite Lived Intangible Assets By Major Class breakouts |
|||
| Customer Related Intangible Assets | 861 | — | — |
| Developed Technology Rights | 264 | 316 | -16.5% |
| Noncompete Agreements | 82 | 25 | +228.0% |
| Trademarks And Patents Member | 1,051 | 457 | +130.0% |
| Other Assets | |||
| Intangible Assets Net Including Goodwill | 13,698 | 11,014 | +24.4% |
| Current Liabilities | |||
| Accounts Payable | 37,834 | 32,812 | +15.3% |
| Long Term Debt And Capital Lease Obligations Current | 671 | 543 | +23.6% |
| Other Accrued Liabilities Current | 3,484 | 3,307 | +5.4% |
| Total Current Liabilities | 41,989 | 36,662 | +14.5% |
| Non-Current Liabilities | |||
| Deferred Tax And Other Liabilities Noncurrent | 9,127 | 7,971 | +14.5% |
| Total Liabilities (Q) | — | — | — |
Show Consolidated Entities breakouts |
|||
| Variable Interest Entity Primary Beneficiary | -776 | -249 | -211.6% |
| Other Liabilities | |||
| Long Term Debt And Capital Lease Obligations | 8,245 | 7,136 | +15.5% |
| Stockholders' Equity | |||
| Common Stock | 2,815 | 2,946 | -4.4% |
| Retained Earnings | 1,732 | 664 | +160.8% |
| Treasury Stock Value | -7,218 | -6,382 | -13.1% |
| Accumulated Other Comprehensive Income | -161 | -176 | +8.5% |
| Total Stockholders' Equity | -2,832 | -2,948 | +3.9% |
| Minority Interest | 160 | 1,050 | -84.8% |
| Stockholders Equity Including Portion Attributable To Noncontrolling Interest | -2,672 | -1,898 | -40.8% |
Show Equity Components breakouts |
|||
| Accumulated Foreign Currency Adjustment Including Portion Attributable To Noncontrolling Interest | -138 | -151 | +8.6% |
| Accumulated Gain Loss Net Cash Flow Hedge Noncontrolling Interest | -23 | -25 | +8.0% |
| Accumulated Other Comprehensive Income | -161 | -176 | +8.5% |
| Aoci Including Portion Attributable To Noncontrolling Interest | -161 | -176 | +8.5% |
| Common Stock | 2,815 | 2,946 | -4.4% |
| Noncontrolling Interest | 160 | 1,050 | -84.8% |
| Retained Earnings | 1,732 | 664 | +160.8% |
| Total Liabilities & Equity | 56,689 | 49,871 | +13.7% |
| Common Stock Shares Authorized | 755 | 755 | 0.0% |
| Common Stock Shares Issued | 271 | 271 | 0.0% |
Show Equity Components breakouts |
|||
| Common Stock | 271 | 271 | 0.0% |
| Treasury Stock Common Shares | 36 | 32 | +12.5% |
Show Equity Components breakouts |
|||
| Treasury Stock Common | 36 | 32 | +12.5% |
| Preferred Stock Shares Authorized | 500 | 500 | 0.0% |
Cash Flow Statement
| Metric | YTD Q3 2026 | YTD Q3 2025 | YoY |
|---|---|---|---|
| Operating Activities | |||
| Depreciation & Amortization | 715 | 581 | +23.1% |
Show Business Segments breakouts |
|||
| All Other Segments · Operating Segments | 85 | 89 | -4.5% |
| Cost of product sold · Operating Segments | 164 | 165 | -0.6% |
| Pharmaceutical and Specialty Solutions · Operating Segments | 195 | 117 | +66.7% |
Show Consolidation Items breakouts |
|||
| Corporate Non Segment | 271 | 210 | +29.0% |
| Gain Loss On Sale Of Other Investments | -20 | -2 | -900.0% |
| Stock-Based Compensation | 309 | 91 | +239.6% |
| Provision For Doubtful Accounts | 47 | 41 | +14.6% |
| Increase Decrease In Receivables | -215 | -367 | +41.4% |
| Change in Inventory | -1,185 | -1,209 | +2.0% |
| Change in Accounts Payable | 3,013 | 954 | +215.8% |
| Repurchases Of Liability Classified Units | -27 | — | — |
| Increase Decrease In Other Operating Capital Net | -673 | -527 | -27.7% |
| Net Cash from Operations | 3,482 | 877 | +297.0% |
| Investing Activities | |||
| Payments To Acquire Businesses Net Of Cash Acquired | 1,967 | 3,855 | -49.0% |
| Capital Expenditures | -385 | -315 | -22.2% |
| Proceeds From Sale Of Property Plant And Equipment | 31 | 3 | +933.3% |
| Net Cash from Investing | -2,303 | -3,962 | +41.9% |
| Financing Activities | |||
| Proceeds From Issuance Of Debt | 991 | 2,869 | -65.5% |
| Repayments Of Long Term Debt | -637 | -434 | -46.8% |
| Payments To Minority Shareholders | 8 | 7 | +14.3% |
| Netproceedstaxwithholdingsfromsharebasedcompensation | -79 | -12 | -558.3% |
| Payments Of Dividends Common Stock | -371 | -374 | +0.8% |
| Share Repurchases | -1,008 | -765 | -31.8% |
Show Equity Components breakouts |
|||
| Common Stock | 50 | — | — |
| Treasury Stock Common | -1 | -750 | +99.9% |
| Share Repurchases (Q) | — | — | — |
Show Share Repurchase Program breakouts |
|||
| $250 million share repurchase program [Member] | -250 | — | — |
| Net Cash from Financing | -1,112 | 1,277 | -187.1% |
| Other Cash Flow | |||
| Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | -4 | 1 | -500.0% |
| Net Change in Cash | 63 | -1,807 | +103.5% |
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | 3,937 | 3,326 | +18.4% |
| Increase Decrease In Other Investing Items Net | -9 | -2 | -350.0% |
| Proceedsfromsaleofavailableforsalesecuritiesandotherinvestments | 27 | 7 | +285.7% |
Values in millions USD. Source: SEC EDGAR 10-Q filing.